Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 202Recurrence 52Neoplasms, Plasma Cell 19Neoplasms 13Immunoglobulin Light-chain Amyloidosis 10Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Myeloproliferative Disorders 4Lymphoma, B-Cell 4Hematologic Diseases 4Amyloidosis 4Waldenstrom Macroglobulinemia 3Sarcoma, Kaposi 3Renal Insufficiency 3Primary Myelofibrosis 3Polycythemia Vera 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Burkitt Lymphoma 3Blood Protein Disorders 3Plasmacytoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Lymphoma, Follicular 2Disease Progression 2Chromosome 17 deletion 2Central Nervous System Neoplasms 2Acquired Immunodeficiency Syndrome 2Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1

Interventions

Carboplatin 13Temozolomide 11Filgrastim 9Radiotherapy 6Etoposide 6Vincristine 5Irinotecan 4Granulocyte Colony-Stimulating Factor 4etoposide phosphate 3Peripheral Blood Stem Cell Transplantation 3O(6)-benzylguanine 3Ifosfamide 3Busulfan 3Vorinostat 2Topotecan 2Radiotherapy, Intensity-Modulated 2Psychiatric Rehabilitation 2Oxaliplatin 2Melphalan 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Doxorubicin 2Cyproheptadine 2Cyclophosphamide 2Cilengitide 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2veliparib 1trioctyl phosphine oxide 1tipifarnib 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Optic Nerve Glioma × pomalidomide × Clear all
NCT02415153 2022-04-25

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled
CNS

Neurofibromatosis 1, Central Nervous System Neoplasms, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡